Plain language summary {#S0001}
======================

We conducted this population-based study to: (i) describe the health service use and costs in the last 90 days of life, as well as place of death among individuals with chronic lung diseases such as COPD and/or lung cancer; (ii) identify predictors of receiving home palliative care; and (iii) assess benefits associated with palliative care in these populations.

Our findings from a large population-based study suggest that home palliative care services were underutilized in both COPD and lung cancer populations, and that increased use of home palliative care services in the last three months of life has the potential to reduce costs and influence the place of death.

To our knowledge, this study is the first large population-based study to report the predictors of palliative care use among decedents with COPD and/or lung cancer and assess the benefits associated with palliative care at the population level for both diseases across health sectors.

Introduction {#S0002}
============

Chronic obstructive pulmonary disease (COPD) and lung cancer are respiratory diseases that are associated with morbidity, progressive deterioration, and high health care utilization.[@CIT0001]--[@CIT0008] Individuals with COPD and lung cancer would benefit from palliative care during the last months of life as the symptom burden is high, leading to reduced quality of life.[@CIT0002]--[@CIT0010] Without provision of adequate palliative care at home, individuals with COPD and lung cancer have no recourse but to seek end of life care through hospital admissions.

Despite similar mortality rates and symptom burden among individuals with lung cancer and COPD, previous research suggests that patients with COPD underutilize palliative care services, and may have worse dying experiences compared to patients with lung cancer.[@CIT0011]--[@CIT0018] However, there is a poor understanding of patient-preference and system-level factors associated with the use of palliative care in these populations.

Palliative care has been shown to improve quality of life and mood,[@CIT0019]--[@CIT0021] survival,[@CIT0020] and reduce health care costs[@CIT0022],[@CIT0023] in individuals with lung cancer. However, the impact of palliative care on health care utilization and care-costs is lacking in the COPD population. To improve the systematic delivery and use of palliative care among patients with COPD, a better understanding of the health service requirements needs to be studied at a population level. Currently, the number of population-based studies examining end-of-life care in COPD and lung cancer are limited,[@CIT0014],[@CIT0015],[@CIT0023]--[@CIT0025] and tend to focus on separate aspects of health care utilization for COPD versus lung cancer patients.

Thus, we conducted this population-based study to: (i) understand the health service utilization and costs in the last 90 days of life, as well as place of death among individuals with COPD and/or lung cancer; (ii) identify predictors of receiving home palliative care; and (iii) assess benefits associated with palliative care in these populations.

Methods {#S0003}
=======

Study design {#S0003-S2001}
------------

We conducted a retrospective population-based observational cohort study of all decedents in Ontario, Canada, eligible for provincial health insurance, and described their receipt of health care services in the last 90 days of life captured through linked provincial health administrative databases between April 1, 2010, and March 31, 2015.

The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a Research Ethics Board.

Data sources {#S0003-S2002}
------------

ICES (formerly Institute for Clinical Evaluative Sciences) is an independent, non-profit research institute which holds a comprehensive high-quality collection of administrative claims and billing data in the province of Ontario whose legal status under Ontario's health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. The datasets used for this study are held securely in a deidentified form at ICES and were linked using unique encoded identifiers and analyzed at ICES. Please see details in the data supplement and at <https://datadictionary.ices.on.ca>.

Study population {#S0003-S2003}
----------------

We used the Registered Persons Database to capture all deaths in the province over a 5-year period between April 1, 2010 and March 31, 2015. We identified individuals with prevalent physician-diagnosed COPD from the Ontario COPD Database, using an algorithm previously validated in Ontario -- based on one or more COPD hospital discharges and/or one or more COPD ambulatory care visits after 35 years of age -- with a sensitivity of 85% and specificity of 78%.[@CIT0026] Lung cancer was identified from the Ontario Cancer Registry[@CIT0027]--[@CIT0030] using US Surveillance, Epidemiology and End Results Site Recode definitions as International Classification of Diseases for Oncology -3 code C34.0--C34.9 (<http://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html>).

For the analysis, we stratified our study cohort into individuals with (i) COPD without lung cancer ("COPD only"), (ii) lung cancer without COPD ("lung cancer only"), and (iii) with both concurrent COPD and lung cancer as mutually exclusive groups. Remaining decedents who were not identified as having COPD or lung cancer by our algorithms comprised the final comparison group of individuals with "neither COPD nor lung cancer".

Variable definition {#S0003-S2004}
-------------------

Age was determined at death and stratified by decades. Sex, rural status,[@CIT0031] and neighborhood income quintiles[@CIT0032] were determined at 1 year prior to death. We also examined the prevalence of 17 chronic conditions separately using previously described definitions[@CIT0033]--[@CIT0037] as well as the total number of chronic comorbidities (0--10 and 10+). Among patients with COPD, having concurrent lung cancer, older age, female gender, and comorbidities have been shown to be associated with an increased likelihood of receiving palliative care, regardless of COPD severity.[@CIT0015],[@CIT0038],[@CIT0039] In individuals with lung cancer, older age, female gender, and having fewer comorbidities have been shown to be associated with an increased likelihood of receiving palliative care.[@CIT0023]

Outcomes {#S0003-S2005}
--------

We considered the following outcomes: location of death, receipt of health services, and health care cost in the last 90 days of life.

Location of death was categorized as death in acute care settings (both emergency room visits and hospital admissions), subacute care (complex continuing care facilities), long-term care (nursing homes) and community. We categorized places of care through receipt of health services in different settings of care, which captured the number of days spent in acute care, subacute care, long-term care, and at home with receipt of home care. Palliative home care and physician home visits were defined using Ontario Health Insurance Plan and Home Care databases.[@CIT0040],[@CIT0041] All physician home visits in the last 90 days of life, regardless if billed specifically as a "palliative" service, were considered palliative care in nature. Please see details on definitions in the data supplement ([[Table S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210916.pdf)).

### Health care cost {#S0003-S2005-S3001}

For costing, we took the perspective of the payer, which is the Ontario Ministry of Health and Long-Term Care, to estimate person-level health care expenditures in the last 90 days of life. Methodologies for deriving the unit and total costs for each care episode across all health sectors are described elsewhere.[@CIT0042] All costs were expressed in 2015 Canadian dollars; we inflated past costs using health care-specific yearly consumer index reported by Statistics Canada. Health sector cost for the population was the sum of all costs among decedents captured within each respective sector.

Analysis {#S0003-S2006}
--------

We used frequencies, proportions, means (standard deviations \[SD\]) and medians (interquartile ranges \[IQR\]) as applicable, to describe the study populations separately by group of interest. All statistical tests were two-tailed and *p*\<0.05 was used to determine statistical significance. To address our second objective, we used multivariable logistic regressions to determine the association between decedent characteristics and the receipt of palliative home care and/or physician home visit in the last 90 days for the entire cohort. To address our third objective, for each group of interest, controlling for age, sex, neighborhood income quintile, neighborhood rurality, and number of comorbidities, we estimated (i) multivariable logistic regressions to assess the relationship between receipt of palliative care and odds of death in acute care; (ii) negative binomial regressions to assess the relationship between the receipt of palliative care and total number of days spent in a hospital; and (iii) log-gamma regressions to assess the relationship between the receipt of palliative care and health care cost.[@CIT0043] For modeling purposes, home care was considered a three-level mutually exclusive categorical variable: palliative home care, usual home care without the palliative element (reference group) and no home care of any type. All statistical analyses were performed in the secure environment of ICES following Ontario privacy standards using SAS 9.3 (SAS Institute Inc., Cary, NC).

Results {#S0004}
=======

Study population characteristics {#S0004-S2001}
--------------------------------

There were 445,488 eligible deaths during our 5-year study period: 150,999 (33.9%) individuals had COPD only, 15,638 (3.5%) had lung cancer only, 24,082 (5.4%) had both COPD and lung cancer, and 254,769 (57.2%) had neither. Individuals with COPD, with or without lung cancer were older, had lower income status and more comorbidities, and were more likely to live in rural area compared to individuals with lung cancer only ([Table 1](#T0001){ref-type="table"}).Table 1Population characteristics by the condition of interest, N (%)CharacteristicsCOPD onlyLung cancer onlyCOPD and lung cancerNeither COPD nor lung cancern=150,999n=15,638n=24,082n=254,769**Age, years (at death date)** **Median (IQR)**82 (15)71 (18)74 (14)81 (21) **35--49**2044 (1.35)596 (3.81)238 (0.99)14,083 (5.53) **50--59**8304 (5.50)2320 (14.84)1981 (8.23)23,403 (9.19) **60--69**18,255 (12.09)4090 (26.15)5775 (23.98)33,974 (13.34) **70--79**33,964 (22.49)4494 (28.74)8619 (35.79)47,425 (18.61) **80--89**58,150 (38.51)3434 (21.96)6549 (27.19)83,020 (32.59) **90+**30,282 (20.05)704 (4.50)920 (3.82)52,864 (20.75)**Income quintile (at 1 year prior to death)** **Missing**967 (0.64)74 (0.47)118 (0.49)1568 (0.62) **Lowest**37,692 (24.96)3284 (21.00)6308 (26.19)53,567 (21.03) **Low**32,311 (21.40)3299 (21.10)5347 (22.20)51,547 (20.23) **Middle**29,075 (19.26)3167 (20.25)4562 (18.94)49,874 (19.58) **High**27,170 (17.99)3063 (19.59)4196 (17.42)50,488 (19.82) **Highest**23,784 (15.75)2751 (17.59)3551 (14.75)47,725 (18.73)**Sex (at 1 year prior to death)** **Male**77,781 (51.51)8236 (52.67)13,118 (54.47)121,171 (47.56)**Rurality (at 1 year prior to death)** **Missing**52 (0.03)9 (0.06)10 (0.04)118 (0.05) **Rural (vs urban)**24,528 (16.24)2255 (14.42)4143 (17.20)34,417 (13.51)**Prior comorbidities** **Arrythmia**49,093 (32.51)2211 (14.14)4859 (20.18)57,950 (22.75) **Asthma**44,151 (29.24)1177 (7.53)6018 (24.99)18,645 (7.32) **Cancer**46,958 (31.10)15,638 (100)24,082 (100)94,679 (37.16) **Congestive heart failure**73,982 (49.00)1966 (12.57)6253 (25.97)70,776 (27.78) **Coronary**75,270 (49.85)3844 (24.58)8858 (36.78)88,446 (34.72) **Dementia**42,326 (28.03)1056 (6.75)2163 (8.98)74,030 (29.06) **Diabetes**61,815 (40.94)4438 (28.38)7918 (32.88)89,028 (34.94) **Hypertension**125,232 (82.94)9918 (63.42)17,449 (72.46)188,769 (74.09) **Mood**25,423 (16.84)2462 (15.74)4351 (18.07)38,723 (15.20) **Renal**48,064 (31.83)1843 (11.79)3958 (16.44)60,644 (23.80) **Rheumatoid arthritis**6182 (4.09)376 (2.40)825 (3.43)6974 (2.74) **Stroke**30,402 (20.13)1498 (9.58)2763 (11.47)46,068 (18.08)**Number of chronic conditions** **0**492 (0.33)69 (0.44)10 (0.04)6866 (2.69) **1**2697 (1.79)1603 (10.25)480 (1.99)18,856 (7.40) **2**6992 (4.63)2771 (17.72)1726 (7.17)32,287 (12.67) **3**13,284 (8.80)3370 (21.55)3156 (13.11)43,559 (17.10) **4**19,465 (12.89)3137 (20.06)4044 (16.79)46,372 (18.20) **5**24,204 (16.03)2238 (14.31)4344 (18.04)41,031 (16.11) **6**25,389 (16.81)1378 (8.81)3899 (16.19)31,236 (12.26) **7**23,415 (15.51)660 (4.22)2861 (11.88)19,574 (7.68) **8**17,474 (11.57)286 (1.83)1916 (7.96)9775 (3.84) **9**10,543 (6.98)102 (0.65)1010 (4.19)3794 (1.49) **10 and more**7044 (4.66)24 (0.15)636 (2.64)1419 (0.56)

Outcome description {#S0004-S2002}
-------------------

Description of all outcomes stratified by the group of interest is presented in [Table 2](#T0002){ref-type="table"}.Table 2Location of death, receipt of health care services and cost in the last 90 days of life by the condition of interestOutcomesCOPD OnlyLung Cancer OnlyCOPD and Lung CancerNeither COPD nor Lung Cancern=150,999n=15,638n=24,082n=254,769***Location of death*, N *(%)*** **Acute care**81,014 (53.65)7741 (49.50)12,738 (52.89)119,182 (46.78) **Sub-acute care**11,139 (7.38)2289 (14.64)3467 (14.40)19,353 (7.60) **Long-term care**27,468 (18.19)539 (3.45)1095 (4.55)49,422 (19.40) **Community**31,378 (20.78)5069 (32.41)6782 (28.16)66,812 (26.22)***Receipt of services in the last 90 days of life**Palliative services*, N *(%)*** **Palliative home care visit**19,446 (12.88)8186 (52.35)11,192 (46.47)43,547 (17.09) **Physician home visit**20,632 (13.66)4869 (31.14)6716 (27.89)38,360 (15.06) **Palliative home care or physician home visit**29,882 (19.79)8852 (56.61)12,380 (51.41)58,014 (22.77)***Days in care, mean (SD)*** **Acute care**14.14 (18.41)14.76 (15.69)15.67 (16.61)12.02 (17.47) **Sub-acute care**3.81 (14.75)4.17 (14.10)4.55 (15.03)3.41 (14.01) **Long-term care**20.79 (36.22)3.40 (16.43)4.83 (19.25)20.58 (36.52) **Home care**12.29 (21.85)16.86 (21.12)16.67 (21.42)11.20 (20.99)***Cost in the last 90 days of life, mean (SD)*** **Cost in CA\$^a^**29,176.22 (33,583.07)30,255.49 (23,062.78)30,742.19 (26,271.20)26,047.10 (30,600.21)[^1]

Regardless of the group of interest, approximately 50% of the individuals died in acute care. Individuals with COPD only were less likely to die in community as compared to those with COPD and lung cancer or lung cancer only (20.8%, 28.2%, and 32.4%, respectively). Decedents with lung cancer with or without COPD spent more days in acute and sub-acute care than individuals with COPD only, which also was reflected by the increased cost of these groups.

Compared to individuals with lung cancer only, individuals with COPD only were less likely to receive palliative care (20% vs 57%).

Predictors of the receipt of palliative care {#S0004-S2003}
--------------------------------------------

After adjustment for confounding variables listed above, lung cancer with or without COPD was significantly associated with receiving home palliative care (OR of 4.22, 95% CI: 4.08--4.37 for lung cancer only), while individuals with COPD only were significantly less likely to receive palliative care (OR of 0.82, 95%CI: 0.81--0.84) compared to those with no lung cancer or COPD ([Table 3](#T0003){ref-type="table"}). Other predictors of receiving palliative care included female gender, living in urban areas, higher income, and multiple comorbidities. The relationship between age and receiving palliative care was complex. Being older was significantly associated with increase in physician home visits with the highest likelihood between age of 50 and 79 years old. Being between 50 and 69 years old was associated with a higher likelihood of receiving palliative home care, while being 80 years and older was associated with a decreased likelihood (OR: 0.38, 95%CI: 0.36--0.40), compared to decedents who were 35--49 years old ([Table 3](#T0003){ref-type="table"}).Table 3Predictors of the receipt of palliative home care and/or physician home visit in the last 90 days for individuals with COPD and/or lung cancer experience near the end of life identified using multivariable logistic regression models. Estimates were presented as odds ratio and 95% confidence interval (all *p*-values \<0.0001 \[bold\])PredictorsPhysician home visitsPalliative home careOdds ratio\
(95% confidence interval)Odds ratio\
(95% confidence interval)***Conditions of interest*** Neither COPD nor Lung Cancer**ReferenceReference** COPD and lung cancer**2.18** (2.11--2.25)**3.89** (3.78--4.00) COPD only**0.90** (0.88--0.92)**0.82** (0.81--0.84) Lung cancer only**2.48** (2.39--2.57)**4.22** (4.08--4.37)***Age sub-groups, years*** 35--49**ReferenceReference** 50--59**1.19** (1.12--1.25)**1.24** (1.19--1.30) 60--69**1.23** (1.16--1.29)**1.24** (1.19--1.30) 70--79**1.21** (1.15--1.27)**1.04** (0.99--1.08) 80--89**1.13** (1.07--1.18)**0.64** (0.62--0.67) 90 and older**1.12** (1.06--1.18)**0.38** (0.36--0.40)***Sex*** Female vs Male**1.13** (1.11--1.15)**1.08** (1.06--1.09)***Location of residence*** Rural vs Urban**0.78** (0.75--0.80)**0.93** (0.91--0.95)***Income status, quintiles*** Lowest**ReferenceReference** Low**1.23** (1.20--1.26)**1.23** (1.20--1.26) Middle**1.27** (1.24--1.31)**1.31** (1.28--1.35) High**1.41** (1.37--1.44)**1.42** (1.39--1.46) Highest**1.64** (1.60--1.68)**1.56** (1.52--1.60)***Number of comorbid conditions*** No comorbidities**ReferenceReference** 1**5.43** (4.70--6.26)**9.10** (7.92--10.46) 2**6.19** (5.38--7.13)**10.60** (9.24--12.17) 3**6.18** (5.37--7.11)**10.86** (9.47--12.46) 4**6.07** (5.27--6.98)**9.95** (8.67--11.42) 5**5.86** (5.09--6.75)**8.93** (7.78--10.24) 6**5.82** (5.06--6.70)**7.93** (6.91--9.11) 7**5.73** (4.97--6.60)**7.07** (6.15--8.12) 8**5.94** (5.14--6.85)**6.54** (5.68--7.53) 9**5.97** (5.15--6.91)**5.92** (5.12--6.85) 10 and more**6.06** (5.21--7.05)**5.76** (4.95--6.71)

The effect of the receipt of palliative care services on location of death, days spent in a hospital and health care cost {#S0004-S2004}
-------------------------------------------------------------------------------------------------------------------------

Regardless of disease, crude percentages suggested that individuals who did not receive palliative care in the last 90 days of life died more often in acute care compared to those who received palliative care ([Figure 1](#F0001){ref-type="fig"} and [[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210916.pdf)). The largest differences were observed in decedents with lung cancer with or without COPD. Individuals with lung cancer, regardless of COPD status, who did not receive palliative care, spent more days in acute care compared to those who received palliative care ([[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210916.pdf)). Mean health care costs in the last 90 days of life were less for individuals who received palliative care compared to those who did not, with the largest differences observed among lung cancer patients ([[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210916.pdf)).Figure 1Proportion of decedents who died in hospital, by receipt of palliative care in the last 90 days of life: (**A**) by receipt of palliative home care, and (**B**) by receipt of physician home visits.

After adjustment for confounding variables, the receipt of palliative home care and physician home visits in the last 90 days of life were significantly associated with reduced death in acute care among all groups ([Figure 2A](#F0002){ref-type="fig"}, [[Table S3]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210916.pdf)). Patients with lung cancer only who received a physician home visit and patients with COPD only who received palliative home care had one-third the odds of death in an acute care setting compared to decedents who only received usual home care.Figure 2Adjusted risks of adverse outcomes by receipt of palliative home care (vs usual home care or no home care) and physician home visit (vs no physician home visits) in the last 90 days of life: (**A**) death in acute care (hospital or emergency department), (**B**) more days spent in a hospital (all-causes), and (**C**) higher health care cost.

In terms of acute care days, receipt of physician home visits and palliative home care were significantly associated with fewer days spent in hospital ([Figure 2B](#F0002){ref-type="fig"}, [[Table S4]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210916.pdf)), when compared to decedents who received usual home care in our regression models. The largest effect was observed among individuals with cancer only who received a physician home visit (IRR: 0.68, 95% CI: 0.71--0.65). These trends are also reflected in the average health care cost associated with palliative care services, whereby costs among decedents who received a physician home visits were 15--18% lower and cost among those who received palliative home care were 11--15% lower than individuals who only had usual home care visits ([Figure 2C](#F0002){ref-type="fig"}, [[Table S5]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210916.pdf)).

Discussion {#S0005}
==========

This population-based study of more than 400,000 individuals who died between 2010 and 2015 demonstrates that palliative care was underutilized among individuals with lung cancer and/or COPD in the last 3 months of life. Despite the similarity of health care needs and the available health care system that provides comprehensive care and social supports, palliative care utilization differed between individuals with the two diseases; the proportion of individuals with lung cancer who accessed palliative care was twice the proportion of individuals with COPD. While it may not be surprising, given the challenges in predicting the trajectory of the disease, that decedents with COPD only were less likely to receive palliative care than those with lung cancer, it was interesting that they were also less likely to receive palliative care than people with neither disease. Furthermore, we identified variables that suggest inequitable access to palliative home care in the population. For example, men who were 80 years of age and older with COPD only, living in urban areas, and in the lowest income status were the least likely to receive palliative home care. To our knowledge, this study is the first large population-based study to report the predictors of palliative care use among decedents with COPD and/or lung cancer and assess the benefits associated with palliative care at the population level for both diseases across health sectors.

Our findings are congruent with other studies demonstrating that individuals with COPD received less end of life palliative care, and were more likely to be institutionalized in a long-term care setting, compared with cancer patients.[@CIT0011],[@CIT0014],[@CIT0015],[@CIT0017],[@CIT0018],[@CIT0025],[@CIT0039],[@CIT0044] The reasons for underutilization of palliative care among patients with COPD are multifactorial.[@CIT0045]--[@CIT0047] For example, COPD itself has a longer course of illness with the perception of a less defined prognosis. Further, our study and others have found a high prevalence of COPD among older populations, particularly those in long-term care, where COPD may be a secondary or complicating diagnosis, but not the primary reason for admission, which may result in poorer long-term planning, including for palliative care.[@CIT0048] Moreover, there is a lack of predictive models and guidelines to assist health professionals with the timing of referral to palliative care for patients with noncancer illnesses, and possible confusion as to which provider should initiate the referral.[@CIT0049] Lack of knowledge among providers of the available palliative care resources and the benefits of home palliative care may also limit referrals.[@CIT0050]

Our results also confirm findings that patients with COPD are less likely to die in the community and more likely to die in acute or sub-acute settings, compared to those with only lung cancer[@CIT0024] despite both groups' preference for treatment focused on comfort (rather than on prolonging life).[@CIT0012]

We consistently found evidence that lung cancer co-diagnosis significantly increased the chances of receiving palliative care among individuals with COPD.[@CIT0015] This is consistent with other studies and suggests that concomitant lung cancer diagnosis, not COPD, may be the dominant driver of receiving palliative care for patients with COPD.

We found that the receipt of palliative home care and physician home visits in the last 90 days were associated with less deaths in the acute care setting, fewer days spent in acute care settings, and lower costs with the largest impact in preventing deaths in the acute care setting. This suggests that patients are more comfortable with death in the home setting when they are supported by a palliative care team and as such, do not seek end-of-life care through hospital admissions. The potentially lower cost associated with palliative care was also shown in the population-based study on the National Inpatient Sample database for patient with stage IV lung cancer.[@CIT0023] In general, but not for our conditions of interest, a home-based palliative care program for end-of-life -- which typically is associated with additional hours of support and more specialized palliative care -- has been shown to be associated with less acute care use, lower costs of care, and higher likelihood of dying at home as compared to usual care in a smaller single center study.[@CIT0022]

The strengths of our study include its real-world and population-level relevance, and power to examine the effects of palliative care use. Our study has several limitations. It is challenging to identify individuals with end-stage COPD; therefore, as a proxy, we performed our analysis on deceased individuals in the last 90 days of their life. Thus, it is possible that some individuals included in our analyses did not have end-stage COPD as they may have died from other unrelated causes. Similar to other population-based studies, our results are prone to unmeasured confounding. The death certificate, diagnostic and fee codes used to identify population and outcomes of interest may cause misclassification bias and does not provide information on important aspects of the end-of-life process such as preferences of treatment or decision-making levels. Thus, whether the palliative or acute care administered was in concordance with patients' wishes could not be explored. Further, we may underestimate the percentage of the receipt of palliative care in individuals with COPD only as some of them may receive palliative care as a part of the comprehensive care plan in a long-term care facility or in a hospital. Those individuals may be less likely to receive palliative services than people living in the community and it may therefore not be a true reflection of their level of access.

Conclusion {#S0006}
==========

The findings from our large population-based study suggest that palliative care services were underutilized in both COPD and lung cancer populations, and that increased use of palliative care services in the last three months of life has the potential to reduce costs and influence the place of death. Our findings identify an important care-gap among patients with lung cancer and COPD in the last months of life. Future work should focus on better understanding of disease trajectories in COPD and when is the "right time" to consider palliative care. There is a greater need for understanding the patient and provider perspectives of preferences for care at the end-of-life, identifying systemic inequities in availability of palliative services among patient sub-groups and on designing comprehensive care models to meet patient needs at the end of life.

Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI) and Cancer Care Ontario (CCO), however, the analyses, conclusions, opinions, and statements expressed herein are those of the author, and not necessarily those of CIHI and CCO. No endorsement by CIHI and CCO is intended or should be inferred. This work was supported by a research grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC) to the Health System Performance Research Network (Grant \#06034), the Bruyère Research Institute (BRI) through the Big Data Research Program, and ICES, which is funded by an annual grant from the MOHLTC. The opinions, results, and conclusions reported in this paper are those of the authors and are independent of the funding sources. No endorsement by ICES, BRI, or the Ontario MOHLTC is intended or should be inferred.
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Author contributions {#S0009}
====================

All co-authors were involved in the following: study conception and design, interpretation of data, revising the manuscript critically for the accuracy and important intellectual content, final approval of the version to be published and agreee to be accountable for all aspoects of the work. Tetyana Kendzerska was additionally involved in the literature search and drafting of the manuscript. Robert Talarico was additionally involved in data analyses. Tetyana Kendzerska and Peter Tanuseputro had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosure {#S0010}
==========

The authors declare no relevant competing interests exist in this work.

[^1]: **Notes:** ^a^All costs were expressed in 2015 Canadian dollars; we inflated past costs using health care-specific yearly consumer index reported by Statistics Canada.
